Glenmark Pharmaceuticals Ltd

NSE: GLENMARK BSE: 532296

₹2136.70

(0.58%)

Tue, 10 Mar 2026, 11:26 pm

MTF 5xInvest in Glenmark Pharmaceuticals Ltd with 5x Leverage Buy with MTF

Market Cap603.26B

PE Ratio56.64

Dividend0.23

Health Technology

Pharmaceuticals: Major

24.5K

Glenmark Pharmaceuticals EV/EBITDA Ratio

D/E EV EV/EBITDA P/B P/CF P/E P/S ROE %

Particulars	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Price to earnings ratio	49.02	26.38	19.66	21.04	21.44	16.92	18.09	20.39	28.30	44.86	31.77	26.43	19.22	19.69	7.49	13.51	13.25	44.14	0	41.51
Price to book ratio	10	10.67	8.04	2.47	3.05	3.76	3.47	4.53	5.14	7.11	5.25	4.90	2.66	3.25	0.96	1.86	1.37	1.38	3.44	4.91
Price to sales ratio	6.27	6.86	6.43	1.97	2.86	2.60	2.07	2.50	2.59	3.27	2.95	2.67	1.64	1.87	0.55	1.21	1.01	1.13	2.29	3.26
Price to cash flow ratio	0	147.77	40.23	0	37.10	9.73	12.85	24.70	23.04	69.95	128.71	49.13	10.30	17.22	5.30	15.59	14.38	38.94	0	0
Enterprise value	48.85B	89.88B	132.59B	60.49B	87.28B	96.13B	102.74B	147.12B	178.07B	243.5B	254.32B	278.76B	182.81B	216.58B	98.8B	169.45B	153.74B	169.25B	265.84B	442.22B
Enterprise value to EBITDA ratio	36.21	21.18	16.68	13.51	13.44	16.23	14.38	14.57	13.73	21.28	17.75	13.69	11.30	14.66	6.05	8.04	6.49	10.13	21.58	18.56
Debt to equity ratio	1.87	1.36	0.65	1.31	0.79	1.04	0.93	1	1.10	1.27	0.93	0.96	0.83	0.79	0.85	0.71	0.44	0.49	0.16	0.28
Return on equity %	24.37	57.45	57.36	12.30	16.41	20.64	20.74	23.81	18.87	15.89	19.31	19.89	14.71	16.53	12.86	14.77	11.66	-1.83	-21.93	12.54

Glenmark Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio

The Glenmark Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio is a key financial metric used by investors to evaluate Glenmark Pharmaceuticals Ltd's valuation, profitability, and overall financial performance. Tracking the Glenmark Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.

Glenmark Pharmaceuticals Ltd (NSE: GLENMARK, BSE: 532296) is currently trading at ₹2136.70, with a market capitalization of ₹603.26B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Glenmark Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio is essential for fundamental analysis.

Glenmark Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio Current Value

The current Glenmark Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio stands at 18.56.

The Glenmark Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.

Glenmark Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio Historical Trend

The Glenmark Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio has shown the following historical trend:

2024: 18.56
2023: 21.58
2022: 10.13
2021: 6.49
2020: 8.04

The decline in Glenmark Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio indicates improving financial efficiency or better earnings growth.

What Glenmark Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio Indicates for Investors

The Glenmark Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio plays a crucial role in understanding the company's financial health and valuation.

This ratio is an important metric used in fundamental analysis of Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio Analysis Summary

The Glenmark Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Glenmark Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.

Regular tracking of Glenmark Pharmaceuticals Ltd Enterprise Value to EBITDA Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.

Open Your Free Demat Account Now!

Step into a world of zero fees and limitless opportunities!

Version -5.76

Stocks:

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Explore

Calculators

Popular Calculators

Group Stocks

Others:

NSE BSE CDSL NSDL SEBI MCX MSEI NCDEX NSE IFSC INDIA INX Account Closure Form DP Investor Charter Broker Investor Charter

Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800